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Edited by Hans EklundAbstract Tripeptidyl-peptidase I (TPP I) is a lysosomal amino-
peptidase that sequentially removes tripeptides from small poly-
peptides and also shows a minor endoprotease activity.
Mutations in TPP I are associated with a fatal lysosomal stor-
age disorder – the classic late-infantile form of neuronal ceroid
lipofuscinoses. In the present study, we analyzed the catalytic
mechanism of the human enzyme by using a site-directed muta-
genesis. We demonstrate that apart from previously identiﬁed
Ser475 and Asp360, also Glu272, Asp276, and Asp327 are important
for catalytic activity of the enzyme. Involvement of serine, glu-
tamic acid, and aspartic acid in the catalytic reaction validates
the idea, formulated on the basis of signiﬁcant amino acid se-
quence homology and inhibition studies, that TPP I is the ﬁrst
mammalian representative of a growing family of serine-car-
boxyl peptidases.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ﬁrst carboxyl proteinases that were identiﬁed as being
insensitive to classic inhibitors of aspartyl proteases such as
diazoacetyl-DL-norleucine methyl ester, 1,2-epoxy-3-(p-nitro-
phenoxy)propane, and pepstatin were isolated from Scytali-
dium lignicolum, a wood-destroying fungus, in 1972 [1]. Since
then, numerous other pepstatin-insensitive carboxyl proteases
(PCPs), mostly from bacteria and fungi, have been identiﬁed
and characterized. These enzymes have acidic pH optima
and usually broad substrate speciﬁcity [2–6]. Structure-based
alignment of the amino acid sequences showed that some PCPs
such as peptidases from Pseudomonas sp. 101 (PSCP) and Xan-
thomonas sp. T-22 (XSCP), kumamolisin from Bacillus no-
vosp. MN-32 (KSCP), proteinase J-4 from Bacillus
coagulans, ScpA from Alicyclobacillus sendaiensis, or LYS45
and LYS60 from Amoeba proteus share signiﬁcant homology
[7, review]. Resolution of the crystal structure of two PCPs –
PSCP, recently renamed sedolisin [8], and KSCP [9] – revealed
their topological similarity with subtilisin and a unique cata-
lytic triad with a nucleophilic serine residue, and glutamic acid*Corresponding author. Fax: +1 718 982 6346.
E-mail address: a.golabek@att.net (A.A. Golabek).
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doi:10.1016/j.febslet.2005.01.035and aspartic acid in the active site. Hence, this group of en-
zymes was recently assigned to the subtilisin clan SB as a ser-
ine-carboxyl proteinase (SCP) or sedolisin family of peptidases
(MEROPS classiﬁcation: family S53).
Tripeptidyl-peptidase I (TPP I, CLN2 protein) (EC 3.4.14.9)
is the only peptidase identiﬁed in humans and numerous mam-
mals that shows signiﬁcant homology to the SCP family of
prokaryotes and lower eukaryotes. Naturally occurring muta-
tions in this lysosomal enzyme are associated with the fatal
neurodegenerative lysosomal storage disorder – late-infantile
neuronal ceroid lipofuscinosis [10,11].
The idea that TPP I may belong to a family of PCPs was for-
mulated by Sleat and colleagues [10] on the basis of inhibition
studies and signiﬁcant sequence similarities of TPP I with
PSCP and XSCP. Although initially TPP I was classiﬁed as
a serine protease [12], inhibition studies provided rather incon-
sistent data regarding the eﬀect of serine protease inhibitors on
the activity of TPP I. In some reports, relatively high concen-
trations of serine protease inhibitors were required to produce
inhibition, e.g., 10 mM diisopropylﬂuorophosphate (DFP) or
1 mM diethylpyrocarbonate (DEPC) produced 75% inhibition
according to Page et al. [12]. In some other studies, TPP I was
either resistant to DFP [13–15], or the enzyme was inhibited
very eﬃciently by DFP, but at a high concentration [16].
Another serine protease inhibitor, 3,4-dichloroisocoumarin,
was either shown to relatively eﬃciently inhibit TPP I [16],
or reported to produce only 28% inhibition at 1 mM [12].
Phenylmethylsulfonyl ﬂuoride did not inhibit TPP I activity
[13–15,17] or showed only minor inhibition at millimolar con-
centration [12]. These discrepancies could result partially from
the diﬀerent assay conditions used. Nevertheless, the fact that
only high concentrations of inhibitors were eﬀective also sug-
gested that the catalytic mechanism of TPP I may diﬀer signif-
icantly from that of typical serine proteases.
Most serine proteases contain a catalytic triad of essential
amino acids – serine, histidine, and aspartic acid [18]. Inhibi-
tion of TPP I with DEPC, which speciﬁcally modiﬁes histidine
residues, suggested that histidine can be involved in the cata-
lytic activity of the enzyme [12,14,17]. However, although a re-
cent study showed that Ser475 is the active-site nucleophile of
TPP I [16], the same report also demonstrated that Asp360
and Asp517, not conserved His236, are involved in the catalytic
activity of human TPP I. The potential participation of Glu in
the active site, like in other members of the SCP family, was
not addressed by these authors. On the other hand, recent
computer modeling and analysis of the high-resolution crystal-
lographic structures of KSCP and PSCP [7–9] suggested thatblished by Elsevier B.V. All rights reserved.
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no acid residues – Glu272 and Asp276 – could be involved in the
catalytic mechanism of human TPP I.
Because TPP I is extensively glycosylated [19,20], our eﬀorts
aimed at elucidating its catalytic mechanism on the basis of
crystal structure have been unsuccessful to date. Thus, in an at-
tempt to clarify existing discrepancies regarding the identity of
the catalytically active amino acid residues of TPP I, we em-
ployed site-directed mutagenesis analyses. Here, we show that
apart from Ser475 and Asp360 identiﬁed by Lin et al. [16], also
Glu272, Asp276, and Asp327 are involved in the catalytic activity
of human TPP I.2. Materials and methods
2.1. Materials
Cell culture media and reagents were purchased from Invitrogen. En-
hanced Chemiluminescence (ECL) Kit reagents were from Amersham
Biosciences. The bicinchoninic acid (BCA) kit was from Pierce. The
pcDNA3.1Hygro vector was from Invitrogen. The protease inhibitor
mixture (Complete) and the Lipofectamine transfection reagent were
from Roche Molecular Biochemicals. Restriction enzymes and T4 li-
gase were from New England Biolabs. All other chemicals were from
Sigma. Monoclonal (mAbs 8C4) and aﬃnity-puriﬁed polyclonal anti-
bodies (pAbs) to TPP I were described previously [19,21]. mAbs to lyso-
some-associated membrane protein (LAMP I), hamster-speciﬁc, were
from the Developmental Studies Hybridoma Bank, University of Iowa,
and pAbs against calreticulin were from Aﬃnity Bioreagents. Peroxi-
dase-conjugated secondary antibodies for ECL were from Amersham
Biosciences. Secondary antibodies conjugated to Alexa Fluor 488 and
Alexa Fluor 555 were from Molecular Probes, and secondary antibod-
ies conjugated to Cy3 were from Jackson ImmunoResearch.
2.2. Site-directed mutagenesis
The cDNA encoding wild-type (wt) human TPP I cloned into the
KpnI/NotI site of pcDNA3.1Hygro was described earlier [19]. Mutated
cDNAs were generated using the overlap PCR technique according to
Ho et al. [22] and wtTPP I-encoding plasmid as a template. The codons
for Glu272, Asp276, Asp327, Asp360, and Asp517 were converted to
an Ala codon. The Ser475 codon was replaced by a Leu codon, as in
the naturally occurring mutation in CLN2 [11,19]. The Ser477 codon
was replaced by a Phe codon to increase the probability of obtaining
an incorrectly folded TPP I mutant.
The following primers were used:
Glu272(77)Ala: F – 5 0 cgggccgggattgcggccagtctagatgtgc 3 0 and R –
5 0 gcacatctagactggccgcaatcccggcccg 3 0; Asp276(81)Ala: F – 5 0 gag-
gccagtctagctgtgcagtacctgatgag 3 0 and R – 5 0 ctcatcaggtactgcacagcta-
gactggcctc 3 0; Asp327(132)Ala: F – 5 0 ctgtgagctatggagctgatgaggactccc
3 0 and R – 5 0 gggagtcctcatctagctccatagctcaca 3 0; Asp360(165)Ala: F
– 5 0 cttcgcctcaggtgccagtggggccggg 3 0 and R – 5 0 cccggccccactggcacct-
gaggcgaag 3 0; Ser475(280)Leu: F – 5 0 ggtgtccggaaccttggcctctactccagt
3 0 and R – 5 0 cactggagtagaggccaaggttccggacac 3 0; Ser477(282)Phe: F
– 5 0 ccggaacctcggcctttactccagtgtttggg 3 0 and R – 5 0 cccaaacactggag-
taaaggccgaggttccgg 3 0; Asp517(322)Ala: F – 5 0 ggggcaggactctttgctg-
taacccgtggctgc and R – 5 0 gcagccacgggttacagcaaagagtcctgcccc 3 0. The
numbering of the mutated amino acid residues shown above corre-
sponds to the full-length cDNA of TPP I and is as used in this manu-
script. The numbering corresponding to the mature enzyme is shown in
parentheses. Full-length TPP I cDNAs containing desired mutation(s)
were subcloned into the KpnI/NotI site of pcDNA3.1Hygro. The struc-
tural integrity of each mutated cDNA was veriﬁed by the PCR-medi-
ated dideoxy sequencing of the entire insert.
2.3. Cell culture and transfection
Chinese hamster-ovary (CHO) cells were maintained in F-12 med-
ium supplemented by 10% fetal calf serum (FCS), 2 mM glutamine,
and antibiotics at 37 C in a humidiﬁed atmosphere with 5% CO2.
Cells were transfected either transiently (Asp517Ala mutant) or stably
(all other mutant proteins) by using the Lipofectamine, according to
the manufacturers recommendation. To obtain stable cell lines, cellswere sub-cultured two days after transfection and maintained in selec-
tion medium supplemented by hygromycin B (200 lg/ml). Single colo-
nies were picked up, expanded, and tested for TPP I by using Western
blotting. Cell lines showing the highest TPP I expression were used for
further experiments.
To obtain a high level of TPP I expression for further puriﬁcation, we
used stably transfected CHO cells deﬁcient in dihydrofolate reductase
(CHO-DHFRneg). These cells were transfected with plasmids encoding
wtTPP I and Glu272, Asp276, Asp327, Asp360, and Ser475 mutant proteins
and then they were selected ﬁrst with hygromycin B and then with
increasing concentrations of methotrexate, as described earlier [19].
2.4. SDS–PAGE and Western blotting
Cells were lysed in a buﬀer containing 50 mM Tris, pH 7.4, 1% Tri-
ton X-100, and protease inhibitor mixture (Complete). Protein concen-
tration was determined by using BCA assay and BSA as a standard.
Twenty lg protein of cell lysate or 10 ll of conditioned medium per
lane was loaded onto 10% Tris/Tricine PAGE. Before running on
SDS–PAGE, conditioned media were cleared by centrifugation at
14000 · g for 5 min. Electrophoretically separated proteins were
immunoblotted, as described [19].
2.5. Immunoﬂuorescence microscopy
For double-immunostaining, cells were ﬁxed with methanol for
20 min at 4 C. Non-speciﬁc binding sites were blocked with 10%
FCS in phosphate-buﬀered saline (PBS) for 1 h. After incubation with
primary antibodies diluted in 10% FCS in PBS overnight at 4 C, cells
were washed with PBS and incubated for 1 h at room temperature with
species-speciﬁc secondary antibodies conjugated with ﬂuorescent dyes:
Alexa Fluor 488 (for TPP I; green ﬂuorescence) and either Cy3 or
Alexa Fluor 555 (for LAMP I and calreticulin; red ﬂuorescence) and
then viewed with a Nikon Eclipse E600 laser-scanning confocal micro-
scope. Omission of the primary antibodies was used as a control of the
method.2.6. TPP I activity measurement and kinetic analysis
Measurements of speciﬁc TPP I activity were done, as described [19].
In brief, 5 lg protein of cell lysate pre-incubated for 1 h at pH 3.5 was
incubated in the reaction mixture containing 0.1 mM substrate Ala-
Ala-Phe-7-amino-4-methylcoumarin (AAF-AMC), 100 mM NaCl
and 0.1% Triton X-100 in a total volume of 100 ll of 0.1 M sodium
acetate, for 20 min at 37 C. The reaction was terminated by the addi-
tion of 50 ll of 10% SDS. Liberated AMC was measured ﬂuorometri-
cally on CytoFluor (Applied Biosystems) (excitation 360 nm, emission
460 nm), after alkalizing the solution by adding 50 ll of 1 M Tris–HCl,
pH 9.0.
Kinetic analysis was performed at 37 C in 0.1 M sodium acetate
buﬀer, pH 5.0, 0.1% Triton X-100 also using AAF-AMC as a sub-
strate, essentially as described [23]. Brieﬂy, pre-warmed, serially diluted
substrate was mixed with TPP I, incubated for 10 min at 37 C and the
reaction was terminated, as above. The Km values were calculated by
non-linear regression ﬁt of initial velocity versus substrate to Michae-
lis–Menten equation with the help of GraphPad Prism software. The
kcat values were derived from the equation: Vmax = kcat[E], where [E]
is the enzyme concentration.
2.7. Puriﬁcation of TPP I
Processed, mature TPP I polypeptide was puriﬁed from ten 35 cm
Petri dishes of conﬂuent CHO-DHFRneg cells overexpressing either
wtTPP I or Glu272, Asp276, Asp327, Asp360, and Ser475 mutant proteins.
The cells were lysed in 50 mM sodium acetate, pH 5.0, 1% Triton
X-100 and protease inhibitor cocktail. TPP I was puriﬁed from cell ly-
sates by a combination of SP-Sepharose (cation-exchange) chromatog-
raphy, heparin-agarose aﬃnity chromatography, and concanavalin
A-aﬃnity chromatography, essentially as described [12,14,17]. The
overall yield was 5–20 lg of puriﬁed protein.3. Results and discussion
A comparison of amino acid sequence of TPP I with that of
the three members of the sedolisin family of peptidases, namely
Fig. 2. Western blotting of wtTPP I and TPP I mutants stably
expressed in CHO cells. Ten lg protein of cell lysate (upper panel) and
10 ll serum-free medium conditioned for 24 h (lower panel) were
immunoblotted with mAb 8C4.
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ysis of the high-resolution crystallographic structures of KSCP
and PSCP [8,9] suggested that apart from Ser475 and Asp360,
two other highly conserved amino acid residues – Glu272 and
Asp276 – could be involved in the catalytic mechanism of hu-
man TPP I [7,24], whereas Asp327 could be involved in sub-
strate binding [9]. To test this possibility, we substituted each
amino acid residue potentially involved in the catalytic mech-
anism of the enzyme and stably expressed cDNAs encoding
mutated TPP I in CHO cells. As a control, we used cells stably
expressing wtTPP I, TPP I with point mutation introduced at
non-conservative Ser477, and mock transfected cells.
Human TPP I is synthesized as a pre-proenzyme that con-
tains 19 amino acid signal peptide cleaved oﬀ co-translation-
ally, and a 176 – amino acid propeptide removed during the
maturation process to yield a mature enzyme of 368 amino
acid residues [10,16,25]. By SDS–PAGE analysis, the apparent
molecular mass (Mw) of the proenzyme is 66–68 kDa, and that
of the mature enzyme is 46–48 kDa [16,17,19,26].
To determine the eﬀect of introduced mutations on TPP I
maturation and secretion, sub-conﬂuent cells were transferred
for 24 h to serum-free medium, and then both cell lysates and
secretions were harvested and analyzed by immunoblotting
with mAbs to TPP I. As demonstrated in Fig. 2 (upper panel),
Ser475Leu, Glu272Ala, Asp276Ala, Asp327Ala, and As-
p360Ala mutant proteins displayed polypeptide patterns simi-
lar to that of wtTPP I, with most of the cellular TPP I being in
a 48-kDa, mature form. In contrast, Ser477Phe mutant was ex-
pressed at a low level and exclusively as a 68-kDa polypeptide
(Fig. 2, upper panel, lane 6). Proenzyme of Ser475Leu,
Glu272Ala, Asp276Ala, Asp327Ala, and Asp360Ala mutant
proteins was secreted into the cell culture medium, thus similar
to wtTPP I (Fig. 2, lower panel), whereas Ser477Phe mutant
protein was absent in cell secretions (Fig. 2, lower panel, lane
6). These data indicated that mutations at Ser475, Glu272,
Asp276, Asp327, and Asp360 do not aﬀect the normal processing
of human TPP I expressed in CHO cells. Low cellular levels of
Ser477Phe mutant protein, lack of its maturation and secretion
suggested that TPP I bearing this mutation was incorrectly
folded, and like most misfolded proteins, underwent the endo-
plasmic reticulum-associated degradation [27]. Given our ear-
lier observation that TPP I matures in lysosomes, this
ﬁnding also suggested that Ser475Leu, Glu272Ala, Asp276Ala,
Asp327Ala, and Asp360Ala mutant proteins were correctly
targeted to lysosomes.
To verify this assumption, we analyzed intracellular distribu-
tion of each mutated protein by double-immunolabeling and
laser-scanning confocal microscopy analysis. wtTPP I, and
Ser475Leu, Glu272Ala, Asp276Ala, and Asp360Ala mutant
proteins (Fig. 3) as well as Asp327Ala mutant (not shown) ex-
pressed in CHO cells were mostly localized to lysosomes, asFig. 1. Alignment of amino acid sequence of some bacterial SCPs and hum
residues. The components of the catalytic machinery are underlined. Identical
is based on full-length cDNAs. The following NCBI Accession Nos. were use
(XSCP precursor from Xanthomonas sp. T-22), BAB85637 (KSCP precur
precursor).judged by the co-localization study with LAMP I, a lysosomal
marker. Ser477Phe mutant protein did not co-localize with
LAMP I (Fig. 3), but showed subcellular distribution similar
to calreticulin, an ER marker we used (not shown), conﬁrming
its ER-retention. Thus, except for Ser477Phe, none of the
mutations introduced aﬀected maturation or intracellular
localization of TPP I.
TPP I acts as a lysosomal aminopeptidase that sequentially
removes tripeptides from small polypeptides with unsubsti-
tuted N-terminus [12,14,15,17] and also shows a minor endo-
protease activity [15]. Similar to various other proteases,
TPP I proenzyme is able to autoactivate at acidic pH in vitro
[16,28]. This process leads to removal of the prodomain, gen-
eration of the 48-kDa species, and acquisition of the enzymatic
activity toward a reporter substrate. If TPP I maturation in
vivo proceeded through autoactivation, proteolytic processing
of TPP I with catalytically important amino acids substituted
should not have been possible, which, as we showed above
(Fig. 2), was not the case. However, we demonstrated earlier
that in vivo, an as yet unidentiﬁed lysosomal serine protease
assists in the processing of TPP I proenzyme into the mature
form [19]. Thus, to assess the ability of mutated polypeptides
to autoprocess in vitro, secreted mutant proenzymes were acti-
vated at pH 3.5 for 1 h in the absence and presence of inhibi-
tors of the major classes of proteases (Complete) and then
analyzed by SDS–PAGE and Western blots. As visualized in
Fig. 4 (upper and lower panel), wtTPP I proenzyme was very
eﬃciently autoprocessed in vitro in both the absence and the
presence of protease inhibitors; hence, it was cleaved auto-cat-
alytically. Secreted proenzymes of TPP I mutants were par-
tially processed into the mature, 48-kDa species in the
absence of Complete (Fig. 4, upper panel). However, the pres-
ence of protease inhibitor cocktail led to the almost complete
inhibition of autoprocessing of mutant proteins, except for
Asp327Ala mutant, as depicted in Fig. 4, lower panel. Thesean TPP I encompassing fragments with highly conserved amino acid
or conserved amino acid sequences are in bold. Amino acid numbering
d: BAA07188 (PSCP precursor from Pseudomonas sp. 101), BAA12093
sor from Bacillus novosp. MN-32), and AAH14863 (human TPP I
Fig. 3. Intracellular localization of wtTPP I and mutant proteins
stably expressed in CHO cells. Laser-scanning confocal-microscopy
analysis of CHO cells stably expressing wtTPP I and TPP I mutants
immunostained with pAbs to TPP I (green ﬂuorescence of secondary
antibody labeled with Alexa Fluor 488) and mAbs to LAMP I, a
lysosomal marker (red ﬂuorescence of Cy3-conjugated secondary
antibody). Yellow color on merged images shows colocalization.
Original magniﬁcation: 1000·.
Fig. 4. In vitro autoprocessing of wtTPP I and mutant proteins.
Aliquots of serum-free medium conditioned for 24 h were preincu-
bated at room temperature in the absence or the presence of protease
inhibitors (Complete) (at 4· ﬁnal concentration recommended by the
manufacturer) for 20 min; then media were adjusted to pH 3.5 with
acetic acid and incubated for 1 h at 37 C. Afterwards, proteins were
precipitated with 15% trichloroacetic acid on ice for 30 min, centri-
fuged, washed in ice-cold 70% ethanol, air-dried, dissolved in gel
loading buﬀer and analyzed by Western blotting.
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la, and Ser475Leu mutant proenzymes were unable to auto-
process in vitro, which suggested that the catalytic machinery
of these mutant proteins was compromised.
To further explore this issue, we analyzed kinetic parameters
of mutant proteins. To this end, Ser475Leu, Glu272Ala, As-
p276Ala, Asp327Ala, and Asp360Ala mutant proteins as well
as wtTPP I were puriﬁed from overexpressing CHO-DHFRneg
cell lysates to near homogeneity. As demonstrated in Table 1,
all these mutant proteins had signiﬁcantly reduced hydrolytic
activity in comparison with wtTPP I. The greatest loss of cat-alytic eﬃciency (kcat/Km) showed Ser475Leu mutant protein
(0.4% of wtTPP I), thus conﬁrming the observation of Lin
et al. [16] that Ser475 is a primary catalytic residue in the
TPP I active site. The residues Glu272 and Asp276 in TPP I
are structural homologues of Glu78/Asp82 and Glu80/Asp84 of
KSCP and PSCP, respectively. These residues in KSCP and
PSCP were believed to play the role of proton shuttles, Glu
residue being the ﬁrst proton acceptor [8,9]. Accordingly, our
data indicate that replacement of Glu272 has more profound ef-
fect on catalytic activity of TPP I than substitution of Asp276.
However, we cannot exclude the possibility, which is rather
less likely, that the contamination of Asp276Ala mutant prep-
aration by endogenous, hamster TPP I could be responsible
for the lower catalytic deﬁciency of this mutant protein.
Computer modeling suggested that protonated Asp360 could
help stabilize the electronegative oxygen atom of nucleophilic
Ser475 during the formation of tetrahedral intermediate [8].
Indeed, the catalytic eﬃciency of Asp360 mutant was greatly re-
duced in comparison with wtTPP I, being comparable to that
of Glu272 mutant. Thus, the inability of mutated TPP I with
Ser475, Asp360, Glu272, and Asp276 substituted to auto-process,
together with loss of proteolytic activity of these polypeptides
in spite of their normal folding, intracellular localization and
secretion, corroborate the involvement of these amino acid res-
idues in the catalytic mechanism of TPP I.
Unlike other sedolisins that show endopeptidase activity,
TPP I acts as an exopeptidase that sequentially removes tripep-
tides from polypeptides with unsubstituted N-terminus, dem-
onstrating only minor endoprotease activity. It was proposed
that Asp327 of TPP I provides a structural basis for tripept-
idyl-peptidase activity of TPP I [9]. However, as we evidenced
here, although the catalytic eﬃciency of Asp327Ala mutant
protein was greatly reduced in comparison with wtTPP I, the
aﬃnity of this mutant protein for the tripeptidyl substrate
(Km) was only slightly decreased (the Km was increased by
67%). Furthermore, Asp327Ala mutant did not demonstrate
any activity toward the tripeptidyl substrate with the substi-
tuted N-terminus (Boc-S-F-L-AMC, data not shown). Hence,
our data suggest either that Asp327 is not responsible for the
tripeptidyl-peptidase activity of TPP I or that it is not the sole
structural determinant of this speciﬁcity. At the same time,
Table 1
Kinetic constants for wtTPP I and mutant proteins
Mutant Km (mM)
a kcat (s
1)a kcat/Km (s
1 mM1) Relative kcat/Km (%)
wt TPP I 0.098 41.66 425.10 100
Glu272Ala 0.118 1.54 13.05 3
Asp276Ala 0.105 9.36 89.14 21
Asp327Ala 0.164 4.22 25.73 6
Asp360Ala 0.111 1.52 12.69 3
Ser475Leu 0.076 0.12 1.58 0.4
aKinetic values were obtained by averaging results from two independent experiments, each in three replicates.
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in vitro. Thus, although Asp327 is not a catalytic residue of
the active site, a dramatic eﬀect of Asp327 substitution on
TPP I activity suggests that it plays an important role(s) in
the catalytic mechanism of TPP I, which may include hydrogen
bonding with the substrate or orienting another catalytic
group in the active site. Further studies are needed to elucidate
this issue.
Finally, we tested the role of Asp517 in the catalytic machin-
ery of TPP I given that Lin et al. [16] have found that this res-
idue is crucial for TPP I activity. According to homology
searches, Asp517 aligns well with Asp316 in KSCP and Asp328
in PSCP (amino acid numbering of mature enzymes). Substitu-
tion of these amino acids by mutagenesis led to the loss of
autoprocessing and catalytic activity of KSCP and PSCP
[29]. Analysis of the crystal structure of PSCP and KSCP sug-
gested that these aspartates may play a critical role in calcium-
binding [8,9]. However, our recent, unpublished, experimentalFig. 5. Maturation and intracellular localization of Asp517Ala mutant
protein in transiently transfected CHO cells. Upper panel: Laser-
scanning confocal microscopy analysis of cells immunostained with
mAb 8C4 and secondary antibody conjugated with Alexa 488 (a, green
ﬂuorescence) and calreticulin, an ER marker, and secondary antibody
conjugated with Alexa 555 (b, red ﬂuorescence) shows colocalization
on a composite image (c, yellow color). Original magniﬁcation: 1000·.
Lower panel: Cells transfected with vector only (lane 1), wtTPP I (lane
2), and Asp517Ala mutant protein (lane 3) were analyzed 30 h after
transfection by immunoblotting with mAb 8C4. 20 lg protein per lane.data question the hypothetical role of calcium in TPP I struc-
ture and suggest that in vitro calcium aﬀects neither TPP I
activity or activation nor its thermal stability. Taking into ac-
count that Asp517Ala mutant protein shows predominantly
ER localization (Fig. 5, upper panel), profoundly hampered
maturation (Fig. 5, lower panel), and no enzymatic activity
(not shown), we propose that Asp517 is important for folding
and not for the catalytic mechanism of TPP I.
In summary, our experiments allow us to conclude that
apart from Ser475 and Asp360, also Glu272, Asp276, and
Asp327 participate in the catalytic mechanism of human TPP
I. The involvement of serine, glutamic acid, and aspartic acid
in the catalytic reaction validates the idea that TPP I is the ﬁrst
mammalian representative of a growing family of SCPs.
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